GlobeNewswire

4basebio Launches Enzymatic ssDNA Platform
11/05/2026
4basebio PLC ("4basebio" or the "Company") 4basebio Launches Enzymatic ssDNA Platform Overcomes critical manufacturing and performance bottlenecks associated with traditional chemical synthesis, providing faster and [...]
Rezolute to Participate in Upcoming Investor Conferences
11/05/2026
REDWOOD CITY, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of [...]
Dark Horse Consulting Group and KunTuo Announce Memorandum of Understanding Providing Cell and Gene Therapy Developers with an Accelerated Path to Clinical Development in China
11/05/2026
WALNUT CREEK, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Dark Horse Consulting Group (“DHCG” or “the Group”), a leader in strategic and operational biotherapeutics consulting, and KunTuo Medical Research and Development ( [...]
Erasca Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate ERAS-0015 in Combination with KEYTRUDA® (Pembrolizumab)
11/05/2026
ERAS-0015, a potentially best-in-class pan-RAS molecular glue, is being evaluated in combination with pembrolizumab SAN DIEGO, May 11, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision [...]
MBX Biosciences Provides Obesity Portfolio Update Including Initial Phase 1 Data for MBX 4291 Supporting Potential for Once-Monthly Dosing
11/05/2026
Preliminary blinded data from ongoing Phase 1 trial demonstrated mean weight loss of 7% (range 0-16%) at 8 weeks in first MAD Part B cohort (n=8, including 2 placebo) MBX 4291 generally well tolerated, only one event of [...]
Lexeo Therapeutics Reports First Quarter 2026 Financial Results and Operational Highlights
11/05/2026
SUNRISE-FA 2 open-label, pivotal trial protocol and SAP for LX2006 submitted to FDA in Q1 2026; Awaiting final FDA feedback Multiple presentations highlighting progress across cardiac genetic medicine pipeline and [...]
Gain Therapeutics Reports Financial Results for First Quarter 2026 and Provides Corporate Update
11/05/2026
BETHESDA, Md., May 11, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of [...]
Alpha Tau Announces Groundbreaking Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial, with 100% Local Disease Control, 67% Complete Response Rate, and Favorable Safety Profile Observed - Conference Call Scheduled for 8:30am ET
11/05/2026
- Interim results from the first three brain cancer patients treated; two of whom demonstrated complete response, with total disappearance of all enhancing tumor lesions, per multiple MRI scans since treatment - - One [...]
Conavi Medical Corp. Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants
11/05/2026
PRELIMINARY PROSPECTUS ACCESSIBLE ON SEDAR+ NOT FOR RELEASE OR DISTRIBUTION IN THE UNITED STATES OR FOR DISSEMINATION TO U.S. NEWS WIRE SERVICES TORONTO, May 11, 2026 (GLOBE NEWSWIRE) -- Conavi Medical Corp. ( TSXV: [...]
Fractyl Health Authorized to Initiate First-in-Human Trial of RJVA-001 in the Netherlands: First Gene Therapy Candidate to Enter Clinical Development for Type 2 Diabetes
11/05/2026
Authorization advances Fractyl Health to a dual clinical-stage company, with Revita ® in pivotal development for post-GLP-1 weight maintenance and Rejuva ® entering first-in-human studies for type 2 diabetes First-in- [...]
Actuate Therapeutics Announces FDA Clearance of IND for Oral Elraglusib and Strategic Initiatives to Advance the Elraglusib Development Program
11/05/2026
Elraglusib oral tablet formulation to drive next-phase clinical development and broader clinical use FDA cleared IND for Phase 1/2 study of oral elraglusib in advanced cancer patients, with focus on metastatic melanoma [...]
Sagimet Biosciences to Present Mechanism of Action Data for its FASN Inhibitors at the Society for Investigative Dermatology in Chicago
11/05/2026
Pre-clinical data shows potential for FASN inhibition as mechanism of action to treat acne Phase 3 clinical trial of denifanstat in moderate to severe acne patients for the U.S. planned to initiate in second half of [...]
Apogee Therapeutics Provides Pipeline Progress and Reports First Quarter 2026 Financial Results
11/05/2026
Zumilokibart advancing across multiple indications, with Phase 3 initiation in atopic dermatitis (AD) expected later this year: - APEX Phase 2 Part A 52-week data demonstrated durable maintenance and improved efficacy [...]
Certara Reports First Quarter 2026 Financial Results
11/05/2026
Updates 2026 Guidance to reflect completed divestiture of Regulatory Writing and Medical Writing Business RADNOR, Pa., May 11, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed [...]
Alvotech Announces Completion of FDA Surveillance Inspection at Reykjavik Facility
11/05/2026
- Company remains on track for BLA resubmissions in the second quarter REYKJAVIK, Iceland, May 11, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the [...]
Alvotech announces completion of FDA surveillance inspection at Reykjavik facility
11/05/2026
Company remains on track for BLA resubmissions in the second quarter REYKJAVIK, ICELAND – May 11, 2026 – Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture [...]
Anaveon Announces Presentation of Positive ANV600 Clinical Data at ASCO 2026 and Actively Seeks Partners for its Legacy Oncology Portfolio
11/05/2026
BASEL, Switzerland, May 11, 2026 (GLOBE NEWSWIRE) -- Anaveon, a late-stage preclinical biotechnology company focused on reprogramming the immune system for the treatment of autoimmune and inflammatory diseases, today [...]
ENA Respiratory Successfully Completes First Part of Phase II Study of INNA-051 Nasal Spray Designed to Protect Against Symptomatic Viral Respiratory Infections
11/05/2026
MELBOURNE, Australia, May 11, 2026 (GLOBE NEWSWIRE) -- ENA Respiratory , a clinical-stage pharmaceutical company developing antiviral host defence enhancers to minimize the impact of symptomatic viral respiratory [...]
Bavarian Nordic – Completion of Share Buy-Back Program
11/05/2026
COPENHAGEN, Denmark, May 11, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces that the share buy-back program, which was announced and initiated on March 12, 2026, has now been completed, reaching an aggregate amount of [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum